In response to COVID-19, the Texas State Board of Pharmacy issued a new medication limits rule to help ensure access to specific medications, like chloroquine, hydroxychloroquine, mefloquine or azithromycin. When writing prescriptions, physicians should:
- Prescription must have a written diagnosis consistent with evidence for its use.
- Number of doses is limited to no more than a fourteen (14) day supply.
- HM strongly recommends limiting quantity to what is needed for completion of therapy following discharge.
- No refills permitted.
- For more information:
The FDA issued an Emergency Use Authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate, currently recommended in several countries for treatment of hospitalized COVID-19 patients. The EUA will help facilitate chloroquine phosphate and hydroxychloroquine sulfate availability during the COVID-19 pandemic for treating patients who can’t participate in a clinical trial.
For more information, read the FDA – Emergency Use Authorization for chloroquine and hydroxychloroquine sulfate in the treatment of COVID-19 patients.
If you need help obtaining hydroxychloroquine for a discharging patient, contact your entity hospital pharmacy.